Pterostilbene further decreased tumor growth in mice that received cisplatin plus gemcitabine, suggesting a potentially chemotherapeutic role of pterostilbene for cisplatin treatment of human bladder cancers with oncogenic HRAS. Here, HRAS is linked to urinary bladder cancer.